Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0037315 (sleep apnea)
 8,000 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present paper attempts to replicate Askenasy and Goldstein's (1995) findings of seasonality in rapid eye movement (REM) sleep measures in patients recorded in Israel. Analysis of sleep stage data of 706 nonselected male sleep apnea patients failed to find seasonality in REM sleep measures. In contrast, our data revealed stability of REM time with a maximum difference between seasons of 7.0 minutes. Age differences were found in sleep efficiency, true sleep time, and amount and percentage of REM sleep, with patients over 60 having a lower sleep efficiency, shorter true sleep, and REM sleep time than patients under 60. Rapid eye movement latency was also found to differ according to apnea severity, with patients who had > 40 apneas and hypopneas per hour of sleep having a longer latency than those with fewer apneas and hypopneas.
 ...
PMID:Nonreplicability of seasonal rhythm in REM sleep in a subtropical climate. 938 Oct 58

Over the past 20 years obesity has become a worldwide concern of frightening proportion. The World Health Organization estimates that there are over 400 million obese and over 1.6 billion overweight adults, a figure which is projected to almost double by 2015. This is not a disease restricted to adults - at least 20 million children under the age of 5 years were overweight in 2005 (WHO 2006). Overweight and obesity lead to serious health consequences including coronary artery disease, stroke, type-2 diabetes, heart failure, dyslipidemia, hypertension, reproductive and gastrointestinal cancers, gallstones, fatty liver disease, osteoarthritis and sleep apnea (Padwal et al 2003). Modest weight loss in the obese of between 5% and 10% of bodyweight is associated with improvements in cardiovascular risk profiles and reduced incidence of type 2 diabetes (Goldstein 1992; Avenell et al 2004; Padwal and Majumdar 2007). Orlistat, a gastric and pancreatic lipase inhibitor that reduces dietary fat absorption by approximately 30%, has been approved for use for around ten years (Zhi et al 1994; Hauptman 2000). There is now a growing body of evidence to suggest that Orlistat assists weight loss and that it may also have additional benefits. The aim of this review is to provide a brief update on the current literature studying the efficacy, safety and significance of the use of Orlistat in clinical practice.
 ...
PMID:Obesity management: update on orlistat. 1820 Aug 2